Braveheart

formerly Braveheart BioIPO

Braveheart is a healthcare company in San Francisco, United States, founded in 2025. It has raised $185.0M across 1 round, most recently a $185.0M Series A in November 2025.

Transforming Hypertrophic Cardiomyopathy Care

Employees
1–10
Founded
2025
Business Model
B2B
Total Funding
$185.0M
Last Round
$185.0M Series ANov 2025
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 1 funding round and 6 investors for this company. The full record is or through the API.

About

Braveheart Bio is a late clinical-stage biotechnology company developing novel therapeutics for hypertrophic cardiomyopathy (HCM), a rare heart-muscle disease affecting roughly 1 in 500 people in the United States. Its lead program, BHB-1893, is a selective small-molecule cardiac myosin inhibitor designed to improve heart performance in HCM patients and is advancing through global late-stage clinical development.

Summary

It lists 1–10 employees. It has raised $185.0M in total across 1 round, most recently a $185.0M Series A round in Nov 2025. Investors include Andreessen Horowitz, Forbion Capital Partners and OrbiMed.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
IPOInitial Public OfferingAug 2026
$382.5M

Sign up to see all 2 events

Funding: Series A. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Braveheart on Indexed.vc
<a href="https://indexed.vc/companies/braveheart"><img src="https://indexed.vc/api/badge/company/braveheart" alt="Braveheart on Indexed.vc" width="260" height="76" /></a>